Topical 0.05% Cyclosporine A Eyedrops for Treating Moderate-to-Severe Vernal Keratoconjunctivitis

This study aimed to investigate the efficacy of topical cyclosporine A (CsA) 0.05% in patients with moderate-to-severe vernal keratoconjunctivitis (VKC).
This retrospective study included 37 patients who were admitted to the clinic between January 2015 and December 2015. All patients were diagnosed with moderate-to-severe VKC and treated with topical CsA 0.05% (Restasis Allergan, Inc. CA, USA). The VKC diagnosis was based on patient history and typical clinical signs and symptoms. Sign and symptom scores of each patient were obtained at pretreatment and during treatment (1, 3, and 6 months).
Of the 37 patients, 20 (54.1%) were male and 17 (45.9%) were female. The mean age of the patients was 11.83 ± 4.70 years (6–24 years). The symptom–sign and total scores of the patients were significantly reduced at 1, 3, and 6 months compared with baseline values. Symptom–sign scores also significantly reduced from 1 month to 3 months and from 3 months to 6 months (P < 0.05).
Topical CsA 0.05% is an effective formulation used for treating moderate-to-severe VKC. It may reduce the need for steroids.